156 related articles for article (PubMed ID: 31884472)
1. An Exploratory Phase IIa Study of the PPAR delta/gamma Agonist T3D-959 Assessing Metabolic and Cognitive Function in Subjects with Mild to Moderate Alzheimer's Disease.
Chamberlain S; Gabriel H; Strittmatter W; Didsbury J
J Alzheimers Dis; 2020; 73(3):1085-1103. PubMed ID: 31884472
[TBL] [Abstract][Full Text] [Related]
2. T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer's Disease.
Tong M; Deochand C; Didsbury J; de la Monte SM
J Alzheimers Dis; 2016; 51(1):123-38. PubMed ID: 26836193
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.
Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B
Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255
[TBL] [Abstract][Full Text] [Related]
4. Medium-chain triglycerides improved cognition and lipid metabolomics in mild to moderate Alzheimer's disease patients with APOE4
Xu Q; Zhang Y; Zhang X; Liu L; Zhou B; Mo R; Li Y; Li H; Li F; Tao Y; Liu Y; Xue C
Clin Nutr; 2020 Jul; 39(7):2092-2105. PubMed ID: 31694759
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Cilostazol Administration in Alzheimer's Disease Patients with White Matter Lesions: A Positron-Emission Tomography Study.
Lee JY; Lee H; Yoo HB; Choi JS; Jung HY; Yoon EJ; Kim H; Jung YH; Lee HY; Kim YK
Neurotherapeutics; 2019 Apr; 16(2):394-403. PubMed ID: 30761509
[TBL] [Abstract][Full Text] [Related]
6. A Placebo-Controlled, Parallel-Group, Randomized Clinical Trial of AC-1204 in Mild-to-Moderate Alzheimer's Disease.
Henderson ST; Morimoto BH; Cummings JL; Farlow MR; Walker J
J Alzheimers Dis; 2020; 75(2):547-557. PubMed ID: 32310169
[TBL] [Abstract][Full Text] [Related]
7. Improved Brain Insulin/IGF Signaling and Reduced Neuroinflammation with T3D-959 in an Experimental Model of Sporadic Alzheimer's Disease.
de la Monte SM; Tong M; Schiano I; Didsbury J
J Alzheimers Dis; 2017; 55(2):849-864. PubMed ID: 27802237
[TBL] [Abstract][Full Text] [Related]
8. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial.
Wang T; Huang Q; Reiman EM; Chen K; Li X; Li G; Lin Z; Li C; Xiao S
J Clin Psychopharmacol; 2013 Oct; 33(5):636-42. PubMed ID: 23948786
[TBL] [Abstract][Full Text] [Related]
9. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
[TBL] [Abstract][Full Text] [Related]
10. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
[TBL] [Abstract][Full Text] [Related]
11. Targeting Alzheimer's Disease Neuro-Metabolic Dysfunction with a Small Molecule Nuclear Receptor Agonist (T3D-959) Reverses Disease Pathologies.
Tong M; Dominguez C; Didsbury J; de la Monte SM
J Alzheimers Dis Parkinsonism; 2016 Jun; 6(3):. PubMed ID: 27525190
[TBL] [Abstract][Full Text] [Related]
12. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial.
De Jesus Moreno Moreno M
Clin Ther; 2003 Jan; 25(1):178-93. PubMed ID: 12637119
[TBL] [Abstract][Full Text] [Related]
13. A Phase IIa Randomized Control Trial of VEL015 (Sodium Selenate) in Mild-Moderate Alzheimer's Disease.
Malpas CB; Vivash L; Genc S; Saling MM; Desmond P; Steward C; Hicks RJ; Callahan J; Brodtmann A; Collins S; Macfarlane S; Corcoran NM; Hovens CM; Velakoulis D; O'Brien TJ
J Alzheimers Dis; 2016 Jul; 54(1):223-32. PubMed ID: 27447428
[TBL] [Abstract][Full Text] [Related]
14. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.
Tosun D; Schuff N; Jagust W; Weiner MW;
Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336
[TBL] [Abstract][Full Text] [Related]
15. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.
Alvarez XA; Mouzo R; Pichel V; Pérez P; Laredo M; Fernández-Novoa L; Corzo L; Zas R; Alcaraz M; Secades JJ; Lozano R; Cacabelos R
Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.
Coric V; van Dyck CH; Salloway S; Andreasen N; Brody M; Richter RW; Soininen H; Thein S; Shiovitz T; Pilcher G; Colby S; Rollin L; Dockens R; Pachai C; Portelius E; Andreasson U; Blennow K; Soares H; Albright C; Feldman HH; Berman RM
Arch Neurol; 2012 Nov; 69(11):1430-40. PubMed ID: 22892585
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies.
Alexander GE; Chen K; Pietrini P; Rapoport SI; Reiman EM
Am J Psychiatry; 2002 May; 159(5):738-45. PubMed ID: 11986126
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer's disease: a Phase II multicenter randomised controlled trial.
Xiao S; Wang T; Ma X; Qin Y; Li X; Zhao Z; Liu X; Wang X; Xie H; Jiang Q; Sun L; Luo B; Shang L; Chen W; Bai Y; Tang M; He M; Wu L; Ma Q; Hou D; He J
Age Ageing; 2017 Sep; 46(5):767-773. PubMed ID: 28419192
[TBL] [Abstract][Full Text] [Related]
19. Safety and target engagement profile of two oxaloacetate doses in Alzheimer's patients.
Vidoni ED; Choi IY; Lee P; Reed G; Zhang N; Pleen J; Mahnken JD; Clutton J; Becker A; Sherry E; Bothwell R; Anderson H; Harris RA; Brooks W; Wilkins HM; Mosconi L; Burns JM; Swerdlow RH
Alzheimers Dement; 2021 Jan; 17(1):7-17. PubMed ID: 32715609
[TBL] [Abstract][Full Text] [Related]
20. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
Engler H; Forsberg A; Almkvist O; Blomquist G; Larsson E; Savitcheva I; Wall A; Ringheim A; Långström B; Nordberg A
Brain; 2006 Nov; 129(Pt 11):2856-66. PubMed ID: 16854944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
